Experienced in Abdominal Obesity Metabolic Syndrome

Thomas A. Lutz

Zurich, ZH, CH 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Abdominal Obesity Metabolic Syndrome
Zurich, ZH, CH 
OverviewLocationsClinical Research

Overview

Thomas Lutz practices in Zurich, Switzerland. Mr. Lutz is rated as an Experienced expert by MediFind in the treatment of Abdominal Obesity Metabolic Syndrome. His top areas of expertise are Obesity, Cerebral Hypoxia, Juvenile Idiopathic Arthritis (JIA), Gastric Bypass, and Oophorectomy.

His clinical research consists of co-authoring 193 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Abdominal Obesity Metabolic Syndrome.

Gender
Male

Locations

Zurich, ZH, Switzerland
Other Locations
Liestal, BL, Switzerland
Schlieren, ZH, Switzerland
Bern, BE, Switzerland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
Enrollment Status: Recruiting
Publish Date: February 10, 2026
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JIA)
A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JIA)
Enrollment Status: Completed
Publish Date: October 07, 2022
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
View 1 Less Clinical Trial

193 Total Publications

Pancreatic amylin dynamically reconfigures distributed brain networks governing appetite regulation in mice.
Pancreatic amylin dynamically reconfigures distributed brain networks governing appetite regulation in mice.
Journal: Molecular metabolism
Published: September 25, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Lutz's expertise for a condition
ConditionClose
View All 21 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile